JP2017531665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531665A5 JP2017531665A5 JP2017519568A JP2017519568A JP2017531665A5 JP 2017531665 A5 JP2017531665 A5 JP 2017531665A5 JP 2017519568 A JP2017519568 A JP 2017519568A JP 2017519568 A JP2017519568 A JP 2017519568A JP 2017531665 A5 JP2017531665 A5 JP 2017531665A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- zinc
- copper
- complex
- iron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14187885.0 | 2014-10-07 | ||
| EP14187885.0A EP3006045B3 (en) | 2014-10-07 | 2014-10-07 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs |
| PCT/EP2015/073196 WO2016055550A1 (en) | 2014-10-07 | 2015-10-07 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017531665A JP2017531665A (ja) | 2017-10-26 |
| JP2017531665A5 true JP2017531665A5 (cg-RX-API-DMAC7.html) | 2018-11-15 |
Family
ID=51751911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017519568A Pending JP2017531665A (ja) | 2014-10-07 | 2015-10-07 | ペプチド又はタンパク質薬物を経口送達するための医薬製剤 |
Country Status (16)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3006045T3 (en) | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
| EP3359181A1 (en) * | 2015-10-07 | 2018-08-15 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide drugs |
| ES2904891T3 (es) | 2016-04-18 | 2022-04-06 | Radius Health Inc | Formulaciones de abaloparatida, parche transdérmico de la misma y usos de la misma |
| EP4265296A3 (en) * | 2016-09-29 | 2023-12-20 | Arecor Limited | Pharmaceutical formulation comprising an insulin compound |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| SG10201609137PA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Gamma-polyglutamic acid and zinc compositions |
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| CN109381695A (zh) * | 2017-08-09 | 2019-02-26 | 武汉武药科技有限公司 | 一种门冬氨酸帕瑞肽注射液及其制备方法和用途 |
| BR112020002804A2 (pt) | 2017-08-24 | 2020-07-28 | Novo Nordisk A/S | composição farmacêutica líquida, e, kit |
| TWI751379B (zh) * | 2017-09-21 | 2022-01-01 | 奧孟亞股份有限公司 | 用於遞送胜肽之藥物組合物 |
| WO2019078663A2 (ko) * | 2017-10-20 | 2019-04-25 | 주식회사 노브메타파마 | 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 |
| CN108079280B (zh) * | 2017-12-30 | 2021-06-04 | 陕西慧康生物科技有限责任公司 | 治疗ⅱ型糖尿病的艾塞那肽滴鼻剂 |
| US12649000B2 (en) | 2018-03-19 | 2026-06-09 | Algipharma As | Use of alginate oligomers to enhance the translocation of micro/nanoparticles across mucus layers |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CN108721598B (zh) * | 2018-07-03 | 2020-06-05 | 北京市新里程医药科技有限公司 | 一种缩宫素原料的制备方法及其药物组合物和制剂 |
| PL3886814T3 (pl) | 2018-11-26 | 2025-04-07 | The Procter & Gamble Company | Stały preparat farmaceutyczny zawierający kwas liponowy i jego zastosowanie |
| CN110251661B (zh) * | 2018-12-12 | 2022-09-16 | 福州市台江区希吉亚健康科技有限公司 | 一种用于治疗糖尿病或者减肥的药物制剂 |
| CN110251662B (zh) * | 2018-12-12 | 2023-01-31 | 福州市台江区希吉亚健康科技有限公司 | 一种具有减肥作用的药物 |
| KR102327750B1 (ko) * | 2018-12-19 | 2021-11-18 | 대화제약 주식회사 | Glp-1 유사체를 포함하는 경구투여용 약제학적 조성물 |
| WO2020183318A1 (en) * | 2019-03-08 | 2020-09-17 | Anya Biopharm Inc. | Oral formulation and treatment of pth analog. |
| GB201906917D0 (en) * | 2019-05-16 | 2019-07-03 | Intract Pharma Ltd | Novel compositions |
| CN112138148B (zh) * | 2019-06-10 | 2024-04-09 | 苏州兰鼎生物制药有限公司 | 一种生长激素或其类似物的口服药物组合物 |
| CN112057619A (zh) * | 2019-06-10 | 2020-12-11 | 苏州兰鼎生物制药有限公司 | 一种具有降血糖作用的药物组合物 |
| WO2020257260A1 (en) | 2019-06-17 | 2020-12-24 | Massachusetts Institute Of Technology | Formulation of peptide loaded liposomes and related applications |
| JP7311086B2 (ja) * | 2019-08-21 | 2023-07-19 | ブレイン ケミストリー ラブズ | 金属及びl-セリンを含む組成物、並びにその使用 |
| KR102216578B1 (ko) * | 2019-09-05 | 2021-02-17 | 주식회사 아이큐어비앤피 | 테리파라타이드를 포함하는 경구용 약학 조성물 및 이의 제조방법 |
| EP4029493A4 (en) | 2019-09-09 | 2023-10-04 | Taejoon Pharmaceutical Co., Ltd. | OPHTHALMIC NANOEMULSION COMPOSITION WITH CYCLOSPORIN AND MENTHOL AND METHOD FOR THE PRODUCTION THEREOF |
| CN113509544B (zh) * | 2019-12-14 | 2024-04-09 | 苏州兰鼎生物制药有限公司 | 一种具有降血糖作用的药物组合物 |
| CN112972659A (zh) * | 2019-12-14 | 2021-06-18 | 苏州兰鼎生物制药有限公司 | 一种特立帕肽或阿巴洛肽的口服药物组合物 |
| CN112972650B (zh) * | 2019-12-14 | 2024-04-09 | 苏州兰鼎生物制药有限公司 | 一种生长抑素或其类似物的口服药物组合物 |
| CN112972658B (zh) * | 2019-12-14 | 2024-04-09 | 苏州兰鼎生物制药有限公司 | 一种生长激素或其类似物的口服药物组合物 |
| CN112972692A (zh) * | 2019-12-14 | 2021-06-18 | 苏州兰鼎生物制药有限公司 | 一种促进肠吸收的药物组合物 |
| CN112972656B (zh) * | 2019-12-14 | 2024-04-09 | 苏州兰鼎生物制药有限公司 | 一种胰高血糖素样肽-2或其类似物的口服药物组合物 |
| CN113171446B (zh) * | 2021-05-06 | 2022-03-29 | 合肥天汇孵化科技有限公司 | 利拉鲁肽组合物及其用途 |
| CN116262134A (zh) * | 2021-12-15 | 2023-06-16 | 联邦生物科技(珠海横琴)有限公司 | 一种稳定的多剂量给药的glp-1受体激动剂的制剂及其制备方法和应用 |
| EP4226918A1 (en) * | 2022-02-15 | 2023-08-16 | Filip Majewski | Pharmaceutical single dosage form for oral delivery of peptides |
| KR102492241B1 (ko) * | 2022-02-25 | 2023-01-30 | 전남대학교산학협력단 | Kitenin의 이량체 형성을 저해하는 펩타이드 및 이의 용도 |
| TW202400219A (zh) * | 2022-04-29 | 2024-01-01 | 香港商鵬躍醫藥科技有限公司 | 用於鼻內給藥的索馬魯肽及其鹽的藥物組合物 |
| CN115161253B (zh) * | 2022-05-30 | 2022-12-02 | 微康益生菌(苏州)股份有限公司 | 一种保持细胞结构完整性的益生菌灭活方法及其应用 |
| CN117357633A (zh) * | 2022-06-30 | 2024-01-09 | 深圳翰宇药业股份有限公司 | 二硫基脂肪酸及其盐在口服递送蛋白质或多肽类药物中的应用 |
| EP4299071A1 (en) * | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| CN114984191B (zh) * | 2022-07-04 | 2022-10-25 | 北京惠之衡生物科技有限公司 | 一种多肽类药物口服递送组合物 |
| WO2024010379A1 (ko) * | 2022-07-05 | 2024-01-11 | 주식회사 지투지바이오 | 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법 |
| KR102844771B1 (ko) * | 2022-07-22 | 2025-08-12 | 주식회사 아이큐어비앤피 | 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법 |
| CN116271064A (zh) * | 2022-09-09 | 2023-06-23 | 中山大学·深圳 | 一种促进利拉鲁肽安全渗透肠细胞的辅料组合物 |
| WO2024077409A1 (en) * | 2022-10-09 | 2024-04-18 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery of therapeutic agents |
| KR102590243B1 (ko) * | 2023-03-13 | 2023-10-20 | 주식회사 에코월드팜 | 수면장애 개선을 위한 l-트립토판 및 키토산을 포함하는 조성물 |
| CN121358465A (zh) | 2023-04-26 | 2026-01-16 | 维沃特克斯公司 | 用于改善渗透的治疗剂的调配物 |
| WO2025037993A1 (en) * | 2023-08-13 | 2025-02-20 | Filip Majewski | Dosage form for peptide agents |
| CN119454605B (zh) * | 2023-11-30 | 2025-12-19 | 深圳奥礼生物科技有限公司 | 一种实现多肽口服吸收的组合物 |
| CN118001411A (zh) * | 2024-04-09 | 2024-05-10 | 深圳奥礼生物科技有限公司 | 一种肠道吸收组合物 |
| CN118105468B (zh) * | 2024-04-23 | 2024-07-16 | 长春生物制品研究所有限责任公司 | 重组人干扰素α2a栓及制备方法 |
| US12544349B1 (en) | 2024-12-30 | 2026-02-10 | Adocia | Compositions comprising pemvidutide and an acylated amino acid |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| AU2610899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| EP1060191B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| DE69916811T2 (de) | 1998-02-27 | 2005-04-14 | Novo Nordisk A/S | Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US20020009490A1 (en) * | 1999-12-22 | 2002-01-24 | Benkendorfer Travis R. | Antiviral therapeutic composition and treatment |
| US20010012829A1 (en) * | 2000-01-11 | 2001-08-09 | Keith Anderson | Transepithelial delivery GLP-1 derivatives |
| WO2003007913A2 (en) | 2001-07-20 | 2003-01-30 | Samir Mitragotri | Method for oral drug delivery |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| EP1686982A4 (en) * | 2003-11-19 | 2007-03-21 | Vecta Ltd | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI USING COMPOUNDS CONTAINING ENDOPEROXIDE BRIDGE |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| JP2007537141A (ja) | 2003-12-18 | 2007-12-20 | ノボ ノルディスク アクティーゼルスカブ | 新規なglp−1化合物 |
| WO2005113592A2 (en) * | 2004-05-19 | 2005-12-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| ES2542228T3 (es) | 2004-07-08 | 2015-08-03 | Novo Nordisk A/S | Marcas de prolongación polipeptídica que comprenden un resto de tetrazol |
| JP2006028031A (ja) * | 2004-07-12 | 2006-02-02 | Ltt Bio-Pharma Co Ltd | 経粘膜吸収用薬物封入ナノ粒子 |
| CN101027318B (zh) * | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
| US20060078623A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| CA2578748C (en) | 2004-09-03 | 2014-10-14 | Kyowa Hakko Kogyo Co., Ltd. | Composition and method for prevention or treatment of stomatitis |
| JP5107713B2 (ja) | 2004-10-07 | 2012-12-26 | ノヴォ ノルディスク アー/エス | 遅延性のエキセンディン−4化合物 |
| JP2008515856A (ja) | 2004-10-07 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 遅延性glp−1化合物 |
| WO2006082245A1 (en) | 2005-02-07 | 2006-08-10 | Novo Nordisk A/S | Pharmaceutical preparations comprising insulin, zinc ions and a zinc-binding ligand |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| ES2484796T3 (es) | 2005-03-18 | 2014-08-12 | Novo Nordisk A/S | Compuestos de GLP-1 extendidos |
| US7618669B2 (en) * | 2005-06-01 | 2009-11-17 | Mead Johnson Nutrition Company | Low-lactose partially hydrolyzed infant formula |
| EP2722054B1 (en) | 2005-09-06 | 2018-03-21 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| US20070086952A1 (en) * | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
| US20090214657A1 (en) * | 2005-11-30 | 2009-08-27 | Muhammad Waseem Tahir Qazi | Orally Absorbed Pharmaceutical Formulation and Method of Administration |
| GB0525461D0 (en) * | 2005-12-15 | 2006-01-25 | Archimedes Dev Ltd | Pharmaceutical compositions |
| EP1969004B1 (en) | 2005-12-28 | 2011-08-10 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| RS60101B1 (sr) * | 2008-08-15 | 2020-05-29 | Ironwood Pharmaceuticals Inc | Formulacije koje sadrže linaklotid za oralnu primenu |
| US20130012454A1 (en) * | 2009-07-06 | 2013-01-10 | Ironwood Pharmaceuticals, Inc. | Orally Disintegrating Compositions of Linaclotide |
| US8748573B2 (en) | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
| CN102596253B (zh) | 2009-09-30 | 2013-11-06 | 蒂奥迈里克斯研究与指导有限公司 | 含有维生素b 亚结构的粘膜粘着聚合物 |
| WO2011116139A2 (en) * | 2010-03-16 | 2011-09-22 | Chiasma Inc. | Improved pharmaceutical compositions and methods of delivery |
| KR20130100897A (ko) | 2010-04-21 | 2013-09-12 | 나노메가 메디컬 코포레이션 | 나노입자의 약제학적 조성물 |
| AU2011252127B2 (en) | 2010-05-10 | 2014-02-20 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| TW201202178A (en) * | 2010-06-04 | 2012-01-16 | Chemo Iberica Sa | Process for producing Aliskiren |
| MX377589B (es) * | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| JP2014502984A (ja) * | 2011-01-19 | 2014-02-06 | ノヴォ ノルディスク アー/エス | Glp−1組成物 |
| WO2012112319A1 (en) | 2011-02-04 | 2012-08-23 | Aegis Therapeutics, Llc | Orally bioavailable peptide drug compositions and methods thereof |
| CN103458873B (zh) | 2011-04-14 | 2016-04-13 | 诺沃—诺迪斯克有限公司 | 用于口服肽递送的脂肪酸酰化的氨基酸 |
| WO2012170828A1 (en) * | 2011-06-10 | 2012-12-13 | Monosol Rx, Llc | Combination peptide-nanoparticles and delivery systems incorporating same |
| US20130004590A1 (en) | 2011-06-28 | 2013-01-03 | Lin Connie B | Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation |
| BR112014005091A2 (pt) * | 2011-09-05 | 2017-06-13 | Beijing Hanmi Pharmaceutical Co Ltd | composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Glp-1 펩티드의 조성물 및 그것의 제조 |
| US20150174076A1 (en) | 2012-06-14 | 2015-06-25 | Entrega, Inc. | Mucoadhesive devices for delivery of active agents |
| HK1215934A1 (zh) * | 2012-12-06 | 2016-09-30 | Stealth Peptides International, Inc. | 肽治疗剂及其使用方法 |
| CN103948915B (zh) * | 2014-05-05 | 2016-06-22 | 德立唯(北京)生物科技有限公司 | 一种能够提高稳定性和口服疗效的用于预防血栓形成和溶栓的纳豆激酶组合物 |
| DK3006045T3 (en) | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
-
2014
- 2014-10-07 DK DK14187885.0T patent/DK3006045T3/en active
- 2014-10-07 EP EP14187885.0A patent/EP3006045B3/en active Active
- 2014-10-07 ES ES14187885.0T patent/ES2630106T3/es active Active
-
2015
- 2015-10-07 EP EP15788340.6A patent/EP3204045B1/en not_active Revoked
- 2015-10-07 RU RU2017115651A patent/RU2017115651A/ru unknown
- 2015-10-07 KR KR1020177009950A patent/KR20170061140A/ko not_active Withdrawn
- 2015-10-07 BR BR112017006957A patent/BR112017006957A2/pt not_active Application Discontinuation
- 2015-10-07 SG SG11201702813VA patent/SG11201702813VA/en unknown
- 2015-10-07 MX MX2017004592A patent/MX2017004592A/es unknown
- 2015-10-07 CN CN201580054091.XA patent/CN106794252A/zh not_active Withdrawn
- 2015-10-07 JP JP2017519568A patent/JP2017531665A/ja active Pending
- 2015-10-07 US US15/517,306 patent/US20170304195A1/en not_active Abandoned
- 2015-10-07 CA CA2960334A patent/CA2960334A1/en not_active Withdrawn
- 2015-10-07 AU AU2015330016A patent/AU2015330016A1/en not_active Withdrawn
- 2015-10-07 WO PCT/EP2015/073196 patent/WO2016055550A1/en not_active Ceased
-
2017
- 2017-03-09 ZA ZA2017/01719A patent/ZA201701719B/en unknown
- 2017-03-30 IL IL251462A patent/IL251462A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025179167A5 (cg-RX-API-DMAC7.html) | ||
| RU2017115651A (ru) | Фармацевтические составы для пероральной доставки пептидных или белковых лекарственных средств | |
| JP2021520391A5 (cg-RX-API-DMAC7.html) | ||
| JP2018529749A5 (cg-RX-API-DMAC7.html) | ||
| US10905744B2 (en) | Pharmaceutical formulations for the oral delivery of peptide drugs | |
| HRP20230799T1 (hr) | Farmaceutski sastavi za isporuku peptida | |
| CA2963659C (en) | Use of oral octreotride compositions | |
| FI3634468T3 (fi) | Suun kautta annettavat kiinteät koostumukset | |
| US20180271792A1 (en) | Oral delivery of physiologically active substances | |
| WO2018065634A1 (en) | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs | |
| CN101180081A (zh) | 稳定的多肽制剂 | |
| US20150065423A1 (en) | Rapid acting injectable formulations | |
| TWI821541B (zh) | Pth類似物之口服製劑及治療 | |
| KR102821435B1 (ko) | 동결 건조된 약학적 제제 및 그의 용도 | |
| CN120076788A (zh) | 在非质子极性溶剂中的稳定的左甲状腺素组合物 | |
| JP2019507174A5 (cg-RX-API-DMAC7.html) | ||
| EP3419649B1 (en) | Stable pharmaceutical compositions comprising insulin glargine and insulin aspart and methods of preparation thereof | |
| EP4631514A1 (en) | Oral polypeptide composition and use thereof | |
| CA3072864C (en) | Pharmaceutical compositions for delivery of peptide | |
| HK40096841A (en) | A polypeptide composition, medicament, pharmaceutical composition and application thereof | |
| RU2020127262A (ru) | Твердые композиции, содержащие агонист glp-1, соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты и смазывающее вещество | |
| RU2023128471A (ru) | Твердые композиции, содержащие агонист glp-1, соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты и смазывающее вещество |